IL4 and neoplasm: Dupilumab, a monoclonal antibody originally designed to treat a wide range of inflammatory conditions, reduces the IL-4-induced pro-tumor phenotype of TAMs by binding to the IL-4 receptor alpha subunit (IL-4Rα) to block IL-4 signaling [74,75].